search
Back to results

Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors

Primary Purpose

Hepatocellular Carcinoma , Cholangiocarcinoma

Status
Recruiting
Phase
Early Phase 1
Locations
China
Study Type
Interventional
Intervention
anti-GPC3 CAR-T cells
Sponsored by
Beijing Immunochina Medical Science & Technology Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma , Cholangiocarcinoma

Eligibility Criteria

18 Years - 69 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • GPC3 expression was positive by histological examination;
  • 18-69 years old;
  • The patients with advanced liver tumor who can not be operated and the effect of chemotherapy is poor;
  • The patients who received traditional palliative therapy had an expected survival period of more than 4 months;
  • Organ status allows clinical application.a. Creatinine < 1.5mg/dl; b. Cardiac ejection index > 55%; c. Heme > 9g / dl, bilirubin < 2.0mg/dl;
  • No bleeding and coagulation disorders were found;
  • There was no allergy to contrast medium;
  • Contraception: contraceptive measures were taken during clinical application and within 3 months after the last cells transfusion;
  • There is no other contraindication for lymphocyte collection;
  • Sign informed consent.

Exclusion Criteria:

  • Pregnant or lactating women;
  • Patients need systemic steroids therapy;
  • At present, the treatment conditions are as follows : a. Within 30 days before the collection of peripheral blood mononuclear cells,patiens were in other anti-tumor clinical observation period; b. Patients have not recovered from the acute side effects of previous treatment;
  • Patients received radiotherapy within 4 weeks after enrollment;
  • Patients received other cell modification therapy in the early stage;
  • In the screening stage, patients with lymphocyte transfection rate less than 5%, or T cell culture can not expand (< 5 times) patients;
  • Uncontrolled symptoms or other diseases include, but are not limited to, infection, congestive heart failure, unstable angina pectoris, arrhythmia, psychosis, or limiting the social environment that meets the requirements, or the researchers believe that they may bring unpredictable risks;
  • Patients with severe acute allergic reactions;
  • Patients who participated in other clinical trials;
  • Researchers believe that patients are not suitable to participate.

Sites / Locations

  • The Fifth Medical Center of Chinese PLA General HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

anti-GPC3 CAR-T

Arm Description

Outcomes

Primary Outcome Measures

Adverse events attributed to the administration of the anti-GPC3 CAR-T cells

Secondary Outcome Measures

Objective response rate (ORR)
Overall survival (OS)

Full Information

First Posted
June 24, 2021
Last Updated
July 1, 2021
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04951141
Brief Title
Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors
Official Title
Beijing Immunochina Medical Science & Technology Co., Ltd.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
December 21, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Objective to study the safety and preliminary efficacy of intratumoral injection of CAR-T cells in the treatment of advanced liver tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma , Cholangiocarcinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
anti-GPC3 CAR-T
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
anti-GPC3 CAR-T cells
Intervention Description
A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
Primary Outcome Measure Information:
Title
Adverse events attributed to the administration of the anti-GPC3 CAR-T cells
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Objective response rate (ORR)
Time Frame
2 years
Title
Overall survival (OS)
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: GPC3 expression was positive by histological examination; 18-69 years old; The patients with advanced liver tumor who can not be operated and the effect of chemotherapy is poor; The patients who received traditional palliative therapy had an expected survival period of more than 4 months; Organ status allows clinical application.a. Creatinine < 1.5mg/dl; b. Cardiac ejection index > 55%; c. Heme > 9g / dl, bilirubin < 2.0mg/dl; No bleeding and coagulation disorders were found; There was no allergy to contrast medium; Contraception: contraceptive measures were taken during clinical application and within 3 months after the last cells transfusion; There is no other contraindication for lymphocyte collection; Sign informed consent. Exclusion Criteria: Pregnant or lactating women; Patients need systemic steroids therapy; At present, the treatment conditions are as follows : a. Within 30 days before the collection of peripheral blood mononuclear cells,patiens were in other anti-tumor clinical observation period; b. Patients have not recovered from the acute side effects of previous treatment; Patients received radiotherapy within 4 weeks after enrollment; Patients received other cell modification therapy in the early stage; In the screening stage, patients with lymphocyte transfection rate less than 5%, or T cell culture can not expand (< 5 times) patients; Uncontrolled symptoms or other diseases include, but are not limited to, infection, congestive heart failure, unstable angina pectoris, arrhythmia, psychosis, or limiting the social environment that meets the requirements, or the researchers believe that they may bring unpredictable risks; Patients with severe acute allergic reactions; Patients who participated in other clinical trials; Researchers believe that patients are not suitable to participate.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fei Wu
Phone
+8615801390058
Email
wufei@immunochina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yin ying Lu, M.D.
Organizational Affiliation
Beijing 302 Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Fifth Medical Center of Chinese PLA General Hospital
City
Beijing
ZIP/Postal Code
100039
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yin ying Lu, M.D.
Email
luyinying1973@163.com

12. IPD Sharing Statement

Learn more about this trial

Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors

We'll reach out to this number within 24 hrs